All visualizations

Weight-loss trials

How to read this chart

How much weight was lost, and over how long?

  1. Read weeks along the bottom and average body weight lost on the vertical axis. The points are study readouts, not predictions for an individual.
  2. Check population, dose and analysis before comparing. Different trials are not head-to-head comparisons. Curves can use a different analysis from the endpoint map.
  3. Select a point for its comparator, safety and source. No uncertainty bar plotted does not mean there is no uncertainty.
Terms in this view
Confidence interval
A range expressing statistical uncertainty around an estimate. It is not the range of individual patients’ outcomes. A 95% interval procedure covers the true value in about 95% of repeated studies under its assumptions. Reference
Absolute versus relative
A fall from 10% to 8% is 2 percentage points lower, or a 20% relative reduction. The starting value and follow-up period matter. Reference
Treatment-policy analysis
Estimates the effect of assigning treatment while including outcomes after specified events such as stopping treatment or using rescue medication. Missing outcomes may still require assumptions. Reference
Efficacy / hypothetical analysis
Often estimates what would happen if participants continued treatment without specified interruptions or rescue therapy. Check the trial definition: this differs from treatment policy and is not automatically a completers-only analysis. Reference

Figures include sources, study context and the current selection.

Weight lossHbA1c

Incretin mimetics, such as GLP-1s, and related weight-loss therapies.

Hormone targets

Includes therapies acting on any selected hormone’s receptors. Meet the hormones.

45 trial endpointsEvidence checked Sep 13, 2026
InjectionOralPhase 3Phase 2Early / phase 1–2Shape = phase of the plotted readout
Weight-loss trial endpointsWeeks of treatment on the horizontal axis and percentage of starting body weight lost on the vertical axis. Each labeled point is a result from a separate trial. Select a point for its study and source.0%5%10%15%20%25%30%012243648607284Body weight lost (%)Weeks of treatmentABBV-295 · 9.79% at 12 weeks · GUC17-01 multiple ascending dose study · Phase 1 readoutABBV-295Aleniglipron · 11.4% at 36 weeks · ACCESS · Phase 2b readoutAleniglipronASC30 · 6.9% at 13 weeks · ASC30-202 · Phase 2 readoutASC30Beinaglutide · 6% at 16 weeks · China phase 3 weight-management trial · Phase 3 readoutBeinaglutideBerobenatide · 12.1% at 28 weeks · VESPER-3 · Phase 2b readoutBerobenatide · monthlyBerobenatide · 12.5% at 28 weeks · VESPER-1 randomized double-blind Part A · Phase 2b readoutBerobenatide · weeklyBGM0504 · 19.2% at 52 weeks · BGM0504-III-WL · Phase 3 readoutBGM0504Bofanglutide · 15.18% at 36 weeks · Bofanglutide US phase 2 obesity trial · Phase 2 readoutBofanglutideCagrilintide · 11.5% at 68 weeks · REDEFINE 1 monotherapy comparator · Phase 3 readoutCagrilintideCagriSema · 20.4% at 68 weeks · REDEFINE 1 · Phase 3 readoutCagriSemaConveglipron · 6.83% at 12 weeks · HDM1002 phase 2 obesity trial · Phase 2 readoutConveglipronCT-996 · 7.3% at 4 weeks · CT-996 multipart phase 1 · Phase 1 readoutCT-996Ecnoglutide · 13.2% at 40 weeks · SLIMMER · Phase 3 readoutEcnoglutideEfsubaglutide alfa · 10.58% at 18 weeks · ENLIGHT phase 2b · Phase 2b readoutEfsubaglutide alfaElecoglipron · 11.8% at 36 weeks · VISTA · Phase 2b readoutElecoglipronEloralintide · 20.1% at 48 weeks · 48-week phase 2 · Phase 2 readoutEloralintideEnicepatide · 22.7% at 48 weeks · CT388-103 · Phase 2 readoutEnicepatideHRS-4729 · 16% at 12 weeks · HRS-4729 phase 1 MAD · Phase 1 readoutHRS-4729HRS-7535 · 9.8% at 44 weeks · HARBOR-1 / HRS-7535-303 · Phase 3 readoutHRS-7535Liraglutide · 8% at 56 weeks · SCALE Obesity and Prediabetes · Phase 3 readoutLiraglutideMariTide · 16.2% at 52 weeks · MariTide phase 2 obesity cohort · Phase 2 readoutMariTideMazdutide · 14.01% at 48 weeks · GLORY-1 · Phase 3 readoutMazdutide 6 mgMazdutide · 19.6% at 60 weeks · GLORY-2 non-T2D subgroup · Phase 3 readoutMazdutide 9 mg*Oral ecnoglutide · 6.8% at 6 weeks · XW004 phase 1 cohort4 · Phase 1 readoutOral ecnoglutideOral ribupatide · 11.4% at 26 weeks · HRS9531 oral phase 2 · Phase 2 readoutOral ribupatideOral semaglutide 25 mg · 13.6% at 64 weeks · OASIS 4 · Phase 3 readoutOral semaglutide 25 mgOrforglipron · 11.2% at 72 weeks · ATTAIN-1 · Phase 3 readoutOrforglipronPemvidutide · 15.6% at 48 weeks · MOMENTUM · Phase 2 readoutPemvidutidePetrelintide · 10.7% at 42 weeks · ZUPREME-1 · Phase 2 readoutPetrelintidePoterepatide · 13.32% at 22 weeks · HDM1005 phase 2 obesity trial · Phase 2 readoutPoterepatideRAY1225 · 21.18% at 24 weeks · REBUILDING-1 · Phase 2 readoutRAY1225Retatrutide · 25% at 80 weeks · TRIUMPH-1 · Phase 3 readoutRetatrutideRibupatide · 17.7% at 48 weeks · GEMINI-1 / HRS9531-301 · Phase 3 readoutRibupatideSemaglutide 2.4 mg · 14.9% at 68 weeks · STEP 1 · Phase 3 readoutSemaglutide 2.4 mgSemaglutide 7.2 mg · 18.7% at 72 weeks · STEP UP · Phase 3b readoutSemaglutide 7.2 mgSurvodutide · 13% at 76 weeks · SYNCHRONIZE-1 · Phase 3 readoutSurvodutideTG103 · 6.47% at 12 weeks · TG103 phase 1b MAD · Phase 1b readoutTG103Tirzepatide · 20.9% at 72 weeks · SURMOUNT-1 · Phase 3 readoutTirzepatideUBT251 · 18.7% at 24 weeks · UBT251 China phase 2 obesity trial · Phase 2 readoutUBT251VK2735 (oral) · 12.2% at 13 weeks · VENTURE-Oral · Phase 2 readoutVK2735 · oralVK2735 (subcutaneous) · 14.7% at 13 weeks · VENTURE · Phase 2 readoutVK2735 · injectionZenagamtide (oral) · 13.1% at 12 weeks · First-in-human phase 1, Part C/D · Phase 1 readoutZenagamtide · oralZenagamtide (subcutaneous) · 24.3% at 36 weeks · Phase 1b/2a, Part B dose escalation · Phase 1b/2a readoutZenagamtide · injectionCagriSema · 20.95% at 68 weeks · REDEFINE 9 · Phase 3 readoutCagriSema 1.0 mgCagriSema · 20.75% at 68 weeks · REDEFINE 9 · Phase 3 readoutCagriSema 1.7 mg

Separate trials, not head-to-head comparisons. Percentages are absolute losses from starting weight, not placebo-adjusted. *Mazdutide 9 mg is the non-diabetic subgroup of a mixed-population trial.

Select a therapy to see the trial, dose, side effects, and source.

All plotted values & sources
Therapy / trial doseTrialWeeksLoss (%)Placebo (%)AnalysisSource
ABBV-295Weekly cohort 5a; dose not separately disclosed (study tested 2–14 mg)GUC17-01 multiple ascending dose studyPhase 1129.790.26Assuming continued treatmentsponsor · 2026-03-09
Aleniglipron120 mg once dailyACCESSPhase 2b3611.41Regardless of stopping treatmentpeer-reviewed · 2026-06-05
ASC3060 mg once dailyASC30-202Phase 2136.9-0.8Other / incompletely specifiedsponsor · 2026-03-31
Beinaglutide0.2 mg three times dailyChina phase 3 weight-management trialPhase 31662.4Other / incompletely specifiedpeer-reviewed · 2024
Berobenatide4.8 mg every 4 weeks after 0.4, 0.8 and 1.2 mg weekly, each for 4 weeksVESPER-3Phase 2b2812.1-0.2Assuming continued treatmentsponsor · 2026-06-06
Berobenatide1.2 mg once weeklyVESPER-1 randomized double-blind Part APhase 2b2812.5-1.7Assuming continued treatmentsponsor · 2026-06-06
BGM050415 mg once weeklyBGM0504-III-WLPhase 35219.23.1Other / incompletely specifiedsponsor · 2026-05-05
Bofanglutide48 mg every two weeksBofanglutide US phase 2 obesity trialPhase 23615.18Not extractedOther / incompletely specifiedsponsor · 2026-06-12
Cagrilintide2.4 mg once weeklyREDEFINE 1 monotherapy comparatorPhase 36811.53Regardless of stopping treatmentsponsor · 2025-02-05
CagriSemaCagrilintide 2.4 mg + semaglutide 2.4 mg once weekly targetREDEFINE 1Phase 36820.43Regardless of stopping treatmentpeer-reviewed · 2025-06-22
Conveglipron400 mg once dailyHDM1002 phase 2 obesity trialPhase 2126.832.88Other / incompletely specifiedsponsor · 2026-06-05
CT-996Once daily; target dose not specified in sourceCT-996 multipart phase 1Phase 147.31.2Other / incompletely specifiedsponsor · 2024-07-17
Ecnoglutide2.4 mg once weeklySLIMMERPhase 34013.2-0.1Regardless of stopping treatmentpeer-reviewed · 2025-06-23
Efsubaglutide alfa20 mg once weeklyENLIGHT phase 2bPhase 2b1810.583.61Other / incompletely specifiedsponsor · 2026-06-05
Elecoglipron75 mg once daily; weekly dose escalationVISTAPhase 2b3611.80.3Assuming continued treatmentsponsor · 2026-06-08
Eloralintide9 mg once weekly48-week phase 2Phase 24820.10.4Assuming continued treatmentsponsor · 2025-11-06
EnicepatideUp to 24 mg once weeklyCT388-103Phase 24822.70.2Assuming continued treatmentsponsor · 2026-06-08
HRS-472912 mg once weeklyHRS-4729 phase 1 MADPhase 112165.4Other / incompletely specifiedsponsor · 2026-05-26
HRS-7535180 mg once dailyHARBOR-1 / HRS-7535-303Phase 3449.82.4Regardless of stopping treatmentsponsor · 2026-07-07
Liraglutide3 mg once dailySCALE Obesity and PrediabetesPhase 35682.6Other / incompletely specifiedpeer-reviewed · 2015-07-02
MariTide420 mg every 4 weeks after 12-week dose escalationMariTide phase 2 obesity cohortPhase 25216.22.5Regardless of stopping treatmentpeer-reviewed · 2025-06-23
Mazdutide6 mg once weeklyGLORY-1Phase 34814.01-0.3Regardless of stopping treatmentpeer-reviewed · 2025-05-24
Mazdutide9 mg once weeklyGLORY-2 non-T2D subgroupPhase 36019.62.79Regardless of stopping treatmentpeer-reviewed · 2026-06-07
Oral ecnoglutide30 mg dailyXW004 phase 1 cohort4Phase 166.80.9Other / incompletely specifiedsponsor · 2024-01-23
Oral ribupatide50 mg once dailyHRS9531 oral phase 2Phase 22611.42.1Regardless of stopping treatmentsponsor · 2026-06-09
Oral semaglutide 25 mg25 mg once dailyOASIS 4Phase 36413.62.2Regardless of stopping treatmentpeer-reviewed · 2025-09-18
Orforglipron36 mg once-daily trial capsule (bioequivalent approved tablet: 17.2 mg)ATTAIN-1Phase 37211.22.1Regardless of stopping treatmentpeer-reviewed · 2025-09-16
Pemvidutide2.4 mg once weeklyMOMENTUMPhase 24815.62.2Other / incompletely specifiedsponsor · 2024-06-23
PetrelintideMaximally effective once-weekly dose; dose level not specified in releaseZUPREME-1Phase 24210.71.7Assuming continued treatmentsponsor · 2026-06-05
Poterepatide4 mg once weeklyHDM1005 phase 2 obesity trialPhase 22213.322.45Regardless of stopping treatmentsponsor · 2026-06-05
RAY122518 mg every two weeksREBUILDING-1Phase 22421.182.96Other / incompletely specifiedsponsor · 2026-06-07
Retatrutide12 mg once weeklyTRIUMPH-1Phase 380253.9Regardless of stopping treatmentsponsor · 2026-05-21
Ribupatide6 mg once weeklyGEMINI-1 / HRS9531-301Phase 34817.71.4Regardless of stopping treatmentsponsor · 2025-11-05
Semaglutide 2.4 mg2.4 mg once weeklySTEP 1Phase 36814.92.4Regardless of stopping treatmentpeer-reviewed · 2021-02-10
Semaglutide 7.2 mg7.2 mg once weeklySTEP UPPhase 3b7218.73.9Regardless of stopping treatmentpeer-reviewed · 2025-09-14
SurvodutideUp to 6.0 mg once weeklySYNCHRONIZE-1Phase 376135.4Regardless of stopping treatmentpeer-reviewed · 2026-06-07
TG10330 mg once weeklyTG103 phase 1b MADPhase 1b126.471.76Other / incompletely specifiedpeer-reviewed · 2024-05
Tirzepatide15 mg once weeklySURMOUNT-1Phase 37220.93.1Regardless of stopping treatmentpeer-reviewed · 2022-06-04
UBT2516 mg once weeklyUBT251 China phase 2 obesity trialPhase 22418.72Assuming continued treatmentsponsor · 2026-06
VK2735 (oral)120 mg once daily after 6-week escalationVENTURE-OralPhase 21312.21.3Other / incompletely specifiedsponsor · 2025-08-19
VK2735 (subcutaneous)15 mg once weeklyVENTUREPhase 21314.71.7Assuming continued treatmentpeer-reviewed · 2026-01-08
Zenagamtide (oral)2 × 50 mg tablets once daily (100 mg total), escalatedFirst-in-human phase 1, Part C/DPhase 11213.11.2Other / incompletely specifiedsponsor · 2025-09-15
Zenagamtide (subcutaneous)Escalation up to 60 mg once weeklyPhase 1b/2a, Part B dose escalationPhase 1b/2a3624.31.1Other / incompletely specifiedpeer-reviewed · 2025-06-20
CagriSemaCagrilintide 1.0 mg + semaglutide 1.0 mg weekly target; flexible dosingREDEFINE 9Phase 36820.952Assuming continued treatmentsponsor · 2026-09-21
CagriSemaCagrilintide 1.7 mg + semaglutide 1.7 mg weekly target; flexible dosingREDEFINE 9Phase 36820.752Assuming continued treatmentsponsor · 2026-09-21
What is included—and how to compare it

This snapshot covers publicly reported adult weight-management trials of GLP-1 medicines, dual and triple agonists, and related amylin therapies. Approved medicines provide context for the investigational pipeline. Diabetes-selected, pediatric, MASH-selected, and withdrawal-maintenance studies are not mixed into the main comparison. Mazdutide 9 mg (marked *) is a reported non-diabetic subgroup of a mixed-population trial.

Each point is one selected study and dose, not a pooled estimate or a drug’s maximum possible effect. A larger general-obesity randomized trial is preferred when usable results exist; within it, the highest planned maintenance dose is normally selected. Separate oral formulations, weekly versus monthly berobenatide regimens, and clinically distinct semaglutide and mazdutide dose programs remain separate. Petrelintide uses the sponsor-designated maximally effective regimen because the release does not specify its milligram dose. CT-996 and ABBV-295 are also retained as explicitly dose-undisclosed early cohorts.

The map prefers treatment-policy or treatment-regimen estimates, which include the consequences of stopping treatment. If unavailable, it uses a clearly labeled efficacy or other analysis. The analysis filter separates these. Older carried-forward analyses, small cohort means, per-protocol results, and incompletely described sponsor estimates are grouped as Other. They are not equivalent to one another.

Results are absolute average percentage losses from starting weight. Placebo values are reported separately; missing placebo values remain missing. A negative placebo loss means weight gain. Trial length, population, dose escalation, lifestyle support, treatment discontinuation and missing-data methods all matter. This plot cannot establish which drug is superior or safer. Uncertainty intervals are not harmonized or displayed; their absence does not imply exactness.

Curves use actual reported visits, from source spreadsheets, printed numerical labels, or explicitly labeled estimates read from published figures. Straight segments connect those visits without fitting or extrapolating. Observed means among remaining participants can differ from a trial’s modeled endpoint. Curve doses and trials can also differ from the endpoint map; each retains its own labels and sources. Curve coverage is curated: absence here does not mean that no published time-course figure exists for that therapy.

Safety summaries are brief study-specific context, not a complete side-effect comparison. Source papers, regulatory labels and trial registries remain the references for detailed safety. Sponsor reports are identified separately from peer-reviewed publications. Development status is a dated research snapshot and does not establish local availability.

Incretins include GLP-1 and GIP. Related amylin therapies are included in this comparison, but amylin is a different pancreatic hormone rather than an incretin. Shape encodes the phase of the plotted study, not a compound’s latest development stage. Hormone filters include any selected receptor target, whether activated or blocked. A documented secondary target does not establish its contribution to the observed weight loss.

September 22 selective addition: REDEFINE 9 lower-dose sponsor endpoints remain separate from the larger REDEFINE 1 policy estimate. No new time-course points were extracted. Other records retain earlier review dates.

October 2 selective update: EloraTZP and eloralintide diabetes results plus TRIUMPH-2 are sourced to September 29–30 reports. Diabetes-selected weight results remain outside the non-diabetic map. Existing endpoints and curves keep their historical sources; no new curve points were extracted.

Other programs & coverage gaps

This is a sourced snapshot, not a complete census of every global trial. Programs below are not assigned an invented or placebo-adjusted point.

  • HRS-1596 · weekly oral GLP-1/GIP

    Phase 1 planned in 122 participants; the September 25 registry still says not yet recruiting. No human efficacy result to plot. Primary completion estimated December 2026; final completion May 2027. Checked September 29.

    Source
  • Olatorepatide

    A sponsor-reported 19.3% mean loss at 48 weeks, n 604; exact arm dose, placebo loss and estimand undisclosed. Do not present as dose-specific comparable endpoint.

    Source
  • Efpeglenatide

    Phase 3 n 448 without diabetes: 9.75% mean loss at 40 weeks verified; public release lacks arm dose, placebo number and estimand. Do not confuse maximum individual 30.14% or subgroup 12.2% with trial mean.

    Source
  • HM15275

    Latest phase 1 poster reports 8 mg regimen, 4.81% placebo-adjusted loss at day 29; no independently verified numeric absolute mean for highest regimen. Cannot plot placebo-adjusted as absolute.

    Source
  • Efocipegtrutide

    Biopsy-confirmed MASH trial; no representative general-obesity without T2D randomized endpoint verified.

    Source
  • DR10624

    Primary human programs target severe hypertriglyceridemia and liver disease; no general-obesity randomized mean loss verified.

    Source
  • Oral BGM0504

    Sponsor reports up to 8.2% over 5–8 weeks US and 5.6% over 4 weeks China; dose/time/arm/estimand mapping insufficient for representative point.

    Source
  • KBP-336

    Amylin/calcitonin receptor agonist; a qualifying absolute human weight-loss endpoint was not located.

    Source
  • GZC8072

    Clinical-trial authorization verified; no randomized human mean weight-loss endpoint located.

    Source
  • Injectable ASC30

    Phase 2 NCT06679959, n=65: three 400 mg monthly doses of formulation A1 produced 7.5% placebo-adjusted mean loss at week 16. Absolute active and placebo means were not located; do not plot 7.5% as absolute. Higher-dose formulation A2 did not attain therapeutic exposures.

    Source
  • AZD6234

    No qualifying public absolute general-obesity monotherapy result located. Current phase 3 adds AZD6234 to stable incretin therapy and includes participants with or without T2D; its results are pending.

    Source
  • VRB-101

    No qualifying absolute weight-loss endpoint located; over 200 participants enrolled for 20-week phase 2b. Earlier phase 1 publication chiefly reports pharmacokinetics.

    Source
  • VRB-103

    Human efficacy result not yet located; once-weekly oral amylin development program.

    Source
  • PF-08653945

    No independently verified qualifying absolute randomized endpoint located. Early mono/combination data expected in 2026; SOLIS-1 evaluates amylin with berobenatide.

    Source
  • Danuglipron

    Historical weight-loss results exist but this is not an active pipeline therapy; no dose-specific absolute endpoint plotted in this dataset.

    Source
  • Lotiglipron

    Not an active pipeline therapy; a qualified dose-specific absolute general-obesity endpoint was not verified.

    Source
  • TERN-601

    Discontinued; sponsor decided October 2025 not to advance TERN-601. Excluded from the active comparison.

    Source
  • Bofanglutide · GRADUAL-1

    A newer phase 3 result reports 18.54% loss at 52 weeks. Diabetes eligibility was not established from the retrieved source, so the map uses the explicitly non-diabetic US phase 2 study.

    Source
  • EloraTZP · obesity with type 2 diabetes

    Phase 2b, 48 weeks: eloralintide 9 mg + tirzepatide 15 mg produced 23.3% weight loss versus 14.8% with tirzepatide and 3.0% with placebo, using an efficacy estimand. The diabetes-selected cohort stays outside the non-diabetic map; its HbA1c result is in the glucose explorer. AMPLIFY co-formulation phase 3 is forecast for Q4 2026, not confirmed started.

    Source
  • Retatrutide · TRIUMPH-2 diabetes cohort

    The September 29 Lancet report gives 18.8% mean weight loss at 80 weeks with 12 mg versus 5.1% with placebo (primary treatment-regimen analysis; n=1,152). This population had type 2 diabetes, so it is retained separately from the non-diabetic TRIUMPH-1 point. The HbA1c explorer includes its separate efficacy-estimand result.

    Source
  • Petrelintide · ZUPREME-2 diabetes cohort

    October 7 ZUPREME-2 topline in type 2 diabetes (28 weeks) reports efficacy-estimand weight loss 7.4–9.2% versus 2.0% and maximum absolute HbA1c reduction 0.65 percentage points versus a 0.23-point placebo increase. Dose-to-result mapping, arm sizes and intervals are missing, so no dose-specific point or curve is plotted. Registry 221 actual participants differs from sponsor 220. The earlier non-diabetic ZUPREME-1 evidence remains unchanged.

    Source

Endpoint map